What is HC Wainwright's Forecast for AKBA FY2026 Earnings?

Key Points

• HC Wainwright cut its FY2026 EPS forecast for Akebia Therapeutics to a loss of $0.18 per share from a previously expected loss of $0.12, while maintaining a Buy rating. The new estimate is below the analyst consensus loss of $0.14 per share.
• Akebia reported a quarterly loss of $0.04 per share, matching consensus, but revenue of $36.9 million fell short of analysts’ $46.94 million expectation.
• Analyst views are mixed: MarketBeat’s average rating is Hold, with an average price target of $3.90.

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Research analysts at HC Wainwright lowered their FY2026 earnings per share estimates for Akebia Therapeutics in a note issued to investors on Friday, November 6th. HC Wainwright analyst M. Caufield now forecasts that the biopharmaceutical company will post earnings of ($0.18) per share for the year, down from their previous estimate of ($0.12). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Akebia Therapeutics' current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Akebia Therapeutics' Q4 2026 earnings at ($0.06) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at ($0.16) EPS, FY2029 earnings at ($0.10) EPS and FY2030 earnings at ($0.05) EPS.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.04). Akebia Therapeutics had a negative return on equity of 88.88% and a negative net margin of 13.54%. The business had revenue of $36.90 million for the quarter, compared to analysts' expectations of $46.94 million.

Other equities research analysts also recently issued reports about the stock. Westpark Capital assumed coverage on shares of Akebia Therapeutics in a report on Tuesday, September 8th. They issued a "buy" rating and a $4.50 price target on the stock. Leerink Partners cut shares of Akebia Therapeutics from an "outperform" rating to a "market perform" rating and set a $1.00 price objective for the company. in a research note on Friday, August 7th. Wall Street Zen lowered shares of Akebia Therapeutics from a "hold" rating to a "sell" rating in a report on Monday. BTIG Research reaffirmed a "buy" rating and set a $4.00 target price on shares of Akebia Therapeutics in a report on Tuesday, September 15th. Finally, Weiss Ratings cut shares of Akebia Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, October 2nd. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Akebia Therapeutics currently has an average rating of "Hold" and an average price target of $3.90.

Akebia Therapeutics Trading Up 32.8%

AKBA stock opened at $0.53 on Tuesday. The stock has a 50-day simple moving average of $0.81 and a two-hundred day simple moving average of $1.12. Akebia Therapeutics has a twelve month low of $0.36 and a twelve month high of $1.89. The company has a quick ratio of 1.35, a current ratio of 1.43 and a debt-to-equity ratio of 0.99.

Institutional Trading of Akebia Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Nantahala Capital Management LLC bought a new position in shares of Akebia Therapeutics in the 2nd quarter worth $2,280,000. BlackRock Inc. purchased a new stake in shares of Akebia Therapeutics during the 2nd quarter valued at $22,784,000. Bank of New York Mellon Corp bought a new stake in shares of Akebia Therapeutics during the 2nd quarter worth $706,000. Canada Pension Plan Investment Board bought a new stake in shares of Akebia Therapeutics during the 2nd quarter worth $369,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Akebia Therapeutics during the 2nd quarter worth $26,000. Hedge funds and other institutional investors own 33.92% of the company's stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease and related conditions. The company's primary areas of interest include anemia associated with chronic kidney disease (CKD), iron deficiency, and disorders involving mineral metabolism.

Akebia's key product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to stimulate the body's natural production of erythropoietin and support red blood cell formation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.